In Brief
Intrinsically disordered regions (IDRs) may serve as functional hubs to regulate protein functions. In this issue of Cell, Meyer et al. showed that disease-causing missense mutations in IDRs create dileucine motifs, which mediate clathrindependent trafficking that underlies disease etiology.
INTRODUCTION
Genome sequencing technologies have greatly facilitated the discovery of human protein variants. In many cases, it is not known whether such variants cause disease, and even when associations have been established, determining the molecular mechanisms remains a major challenge (Cooper and Shendure, 2011) . Most disease-causing missense mutations affect evolutionarily conserved amino acids within structured regions of proteins and destabilize their structure (Subramanian and Kumar, 2006; Yue et al., 2005) . However, over 20% of human disease mutations occur in so-called intrinsically disordered regions (IDRs) (Vacic et al., 2012) . Contrary to the traditional understanding of protein structure and function, it is now clear that IDRs represent a functionally important and abundant part of eukaryotic proteomes (Uversky et al., 2008; Wright and Dyson, 2015) . Yet, because IDRs lack a defined tertiary structure and are typically poorly conserved, the classical structure-function paradigm cannot explain how mutations in IDRs cause disease.
We set out to investigate the mechanism of these mutations by analyzing protein-protein interactions (PPIs), which can help to understand how mutations cause disease (Ryan et al., 2013; Wang and Marcotte, 2010) . The role of PPIs in disease is highlighted by the enrichment of missense mutations in interaction interfaces of proteins associated with the corresponding disorders (Wang et al., 2012) . Moreover, comparing the interaction partners of wild-type proteins and their disease-associated variants can reveal disease mechanisms (Hosp et al., 2015; Zhong et al., 2009) . We therefore sought to systematically investigate how mutations in IDRs affect PPIs.
IDRs often harbor short linear motifs (SLiMs) that mediate their function (Fuxreiter et al., 2007; Van Roey et al., 2014) . These SLiMs typically fall into two major classes-motifs that mediate interactions with globular domains and/or motifs that harbor posttranslational modification sites (Tompa et al., 2014) . Mutations in IDRs can cause disease by disrupting such motifs or by creating novel ones. A number of examples of such pathogenic changes in motifs have been reported (Cordeddu et al., 2009; Kadaveru et al., 2008; Silvis et al., 2003; Vogt et al., 2005) . Additionally, computational studies have revealed that pathogenic mutations often occur in SLiMs (Narayan et al., 2016; Radivojac et al., 2008; Uyar et al., 2014) . Despite these insights, there has not yet been a systematic experimental analysis of how disease-causing mutations in IDRs affect interactions. One reason for this is that the small binding area between SLiMs and cognate domains results in low binding affinities, which makes it difficult to study these interactions (Neduva and Russell, 2005) .
Here, we developed a scalable proteomic screen using synthetic peptides to assess the impact of missense mutations in disordered regions on PPIs. By applying this screen to over 120 known disease-causing mutations, we obtained a network of PPIs that are lost or gained as the result of mutations in disordered regions. Within this network, we identified a subnetwork comprising three mutations and five interacting proteins enriched in terms related to clathrin-dependent trafficking. Intriguingly, all three mutations in this subnetwork create novel dileucine motifs in cytosolic tails of transmembrane proteins. Because dileucine motifs mediate clathrin-dependent trafficking, our findings provide a mechanistic explanation about how these mutations cause disease. Indeed, experiments on the glucose transporter GLUT1 confirmed that the gained dileucine motif causes protein mislocalization by recruiting adaptor proteins and inducing clathrin-dependent endocytosis. In summary, we show that our scalable proteomic screen can reveal the functional consequences of mutations in disordered regions. The data suggest that dileucine motif gains in disordered cytosolic tails of transmembrane proteins are a relatively frequentand potentially druggable-cause of disease.
RESULTS

A Peptide-Based Interaction Screen of Disease-Causing Mutations
We reasoned that quantitative interaction proteomics with immobilized synthetic peptides should enable us to systematically assess the impact of mutations in IDRs. Such peptide pulldowns can maintain specificity even in the setting of low-affinity interactions (Schulze and Mann, 2004) . Peptides can also be directly synthesized on cellulose membranes and used for interaction screens via mass spectrometry (Dittmar et al., 2017; Frank, 2002; Okada et al., 2012) . We followed this strategy to design a scalable proteomic screen ( Figure 1A ): pairs of peptides with 15 amino acids that correspond to IDRs in both the wildtype and mutant form are synthesized on cellulose membranes. These membranes are incubated with cell extracts to pull-down interacting proteins. After washing, peptide spots are excised and the proteins associated with them are identified and quantified by shotgun proteomics.
The main challenge in such interaction screens is to distinguish specific interaction partners from non-specific contaminants (Gingras and Raught, 2012; Gstaiger and Aebersold, 2009; Meyer and Selbach, 2015; Smits and Vermeulen, 2016) . We addressed this challenge through the use of two levels of quantification. First, two replicates of a pull-down with a specific peptide sequence are compared to all other peptide pull-downs via label-free quantification (LFQ) (Cox et al., 2014) . This LFQ-filter selects proteins that bind specifically to a given peptide. Second, the screen employs stable isotope labeling by amino acids in cell culture (SILAC)-based quantification (Mann, 2006) to identify differential interaction partners of the wild-type and diseasecausing form of a peptide. This strategy requires incubating two replicates of the membrane with cell lysates that have been differentially SILAC-labeled. Wild-type peptide spots from the heavy pull-down are combined with spots from the light pulldown that correspond to the mutant forms of the same peptide and vice versa. SILAC ratios give a measure of the degree to which each particular mutations affects a specific interaction.
For the screen, we selected 128 mutations in IDRs that are known to cause neurological diseases ( Figure S1 ; Table S1 ). We included a peptide from an IDR in the SOS1 protein that contains a proline-rich motif by which it is known to recruit several specific binders via their SH3 domains (Schulze and Mann, 2004) . We analyzed the 2 3 129 pull-down samples by using high-resolution shotgun proteomics in 45-min runs, resulting in a total measurement time of $8 days. Replicates of the same peptide clustered with a median correlation coefficient (Pearson's R) of 0.87, indicating good reproducibility ( Figure S2A ). The LFQ data identified nine specific interactors of the SOS1 peptide, including four of the five that were previously known ( Figure 1B ). In the corresponding SILAC data, seven of the nine LFQ-specific binders show preferential binding to the wild-type compared to the mutant, which contains a disrupted prolinerich motif ( Figure 1C ). Importantly, all interactors that are both specific (LFQ) and differential (SILAC) contain SH3 domains. To further assess the relationship between peptide motifs and cognate domains, we analyzed all pull-downs combined. We found that mutations that disrupt a predicted SLiM in the peptide tend to reduce binding of proteins with cognate domains (Figure S2B) . Conversely, the gain of a SLiM in a peptide tends to increase binding to proteins with matching domains. We conclude that our screen efficiently detects how mutations in IDRs affect interactions mediated by SLiMs.
A Quantitative Interaction Network for Disease-Associated IDRs
Individual pull-downs typically led to the identification of $400 proteins. If all of these proteins were specific binders, this would correspond to $400 binary interactions per pulldown and more than 100,000 interactions in total. However, because many proteins are background binders, we applied our quantitative filters with cut-offs derived from the SOS1 control peptide (Figure 2A ). Approximately half of the 2 3 128 peptides showed at least one specific binder according to the LFQ-filter ( Figure S2C ). Applying the LFQ-filter dramatically reduced the total number of interactions to 618. All of these 618 interactions are specific for the wild-type and/or the mutant form of a peptide as compared to all other peptides in the screen (Table S2) . However, not all of these specific (A) Cellulose membranes with synthetic wild-type (circles) and mutated (stars) peptides are incubated with lysate from light (light blue) or heavy (dark blue) SILAClabeled cells to pull-down interacting proteins. Spots are excised, corresponding wild-type/mutant pairs are combined and analyzed by quantitative shotgun proteomics (represented by an Orbitrap). Middle: label-free quantification (LFQ) identifies specific interactors by comparing both replicates to all other pulldowns. Volcano plots depict protein enrichment in in the two replicate pull-downs of a given peptide over all other peptide pull-downs, separately for the wild-type (left) and mutant peptide (right). The threshold (red lines) was derived from the benchmark experiment with the SOS1 peptide (B, for details see STAR Methods). LFQ-specific interactors are depicted in red. SILAC-based quantification identifies differential binders by directly comparing corresponding wild-type and mutant pairs. Differential binders of the wild-type and mutant peptide appear in the upper-right and lower-left quadrants, respectively (for detailed selection criteria see STAR Methods, see also Figure S1 and Table S1 ). (B and C) Results for a SOS1-derived peptide with a SH3 domain-binding PxxP motif as a benchmark. interactions are differential (i.e., affected by the mutation). Therefore, we next applied the SILAC-filter, which led to a final list of 180 differential interactions (Table S3) . 111 of these interactions are lost through mutations in the peptide, while 69 are gained. Of note, because pull-downs can capture indirect binders, not all of these interactions are necessarily direct.
To provide an overview of the data, we displayed the differential interactions as a network ( Figure 2B ). This revealed that several wild-type or mutant peptides shared differential interactors, suggesting functional similarities. Moreover, subnetworks were enriched in specific gene ontology terms (Data S1). SLC2A1_P485L   CLTC   CLINT1   IPO9   CACNA1H_A748V   CD2AP   CAPZA1   AAAS_Q15K   IPO7   PYCR1   RPUSD4   ZC2HC1A   CHTOP   WDR11   G3BP1   NME4   AP2A1   CC2D1A   PRIC295   RRP12   XPO1   CLN6_R6T   DEPDC5_S1073R   EGR2_I268N   ERH   MECP2_G161V   GPHN   GCH1_P23L   VCP   IFT140_E664K   TRAF2   SMPD1_A196P   RCN2   CDKL5_N399T   MYCBP2   MATR3_T622A   SPTAN1   TYMP_R44Q   SSBP1   SETBP1_I871T   DNCL1   GJB1_C280G   POLDIP2   POLRMT   CC2D2A_T1114M   UBR4   P4HB   ZEB2_Q1119R   CKMT1A   MDN1   HUWE1  UBL5   AF1Q   PHGDG   SOD1_I152T   DYNC1H1   ERCC6_P1042L   GJB1_R230C   C1QBP   NOC2L   AP3B1   TCOF1   EARS2_R168G   PANK2_E134G   PTMA   FUS_R216C   CASR_R898Q   SPAST_P293L   HSP90B1   PPM1G   TRPV4_R315W   NAP1L1   CALR   SUPT5H   RUVBL1  RUVBL2   TUBB2B   CALU   UBA1_S547G   IPO11   MAP1B   SSR4   DARS2_Y629C   TPM3   PCNA   PDIA6   RBBP4   CKB   NASP   YWHAZ   RTL1   CCDC47   SEC63   HDGFL2   CTNNBL1  ZC4H2_R213W   TINF2_K280E   SRRM2   DDX39B A) Quantitative filters to select specific and differential interactions. Only a minor fraction of all detected interactions is specific (LFQ filter). Moreover, only a fraction of specific interactions are differential (SILAC filter), i.e., show preferential binding to the wild-type or mutant form of a peptide. Mutation-induced interaction losses are more frequent than mutation-induced gains. See also Figure S2 . (B) Network of all differential interactions. Peptides (rectangles) and interacting proteins (ovals) are presented as nodes. The edges indicate preferential binding to the wild-type (blue) or mutant (red) form of a peptide (edge darkness indicates SILAC ratios). Highlighted subnetworks are enriched in splicing regulators and clathrin-coated vesicle proteins (see text). See also Tables S2 and S3 and Data S1. interesting (insets): one is enriched in proteins connected to clathrin-coated vesicles (see below). The other is enriched in splicing factors that interact with an IDR corresponding to amino acids 512-526 of fused in sarcoma (FUS). These interactions are disrupted by the R521C mutation. FUS is an RNA-binding protein implicated in amyotrophic lateral sclerosis (ALS) (Deng et al., 2014) . R521C and other mutations in the C-terminal region of the protein are thought to cause disease by disrupting a nuclear localization signal (Dormann et al., 2010) . Our data suggest that impaired binding of splicing factors could be an additional/alternative explanation for the pathogenicity of this mutation. Interestingly, FUS has already been implicated in splicing (Ishigaki et al., 2012; Qiu et al., 2014; Rogelj et al., 2012) . In fact, the C-terminal region of the protein was found to interact with serine/argininerich splicing factor 10 (SRSF10) even before pathogenic mutations in this region were identified (Yang et al., 1998) .
Recruitment of Clathrin through Gains of Dileucine Motifs
The finding we considered most interesting is that mutated IDRs from CACNA1H, GLUT1/SLC2A1, and ITPR1 lead to specific interactions with clathrin ( Figure 3A ). The corresponding SILAC data revealed that, in all three cases, clathrin exhibited a strong preference for the mutant form of the peptides over the wild-type ( Figure 3B ). Because clathrin mediates endocytosis and intracellular trafficking of transmembrane proteins, our finding suggests that these mutations might affect protein trafficking. Intriguingly, the three mutations share other features beyond increased clathrin binding: First, all three mutations affect transmembrane proteins-a calcium channel (CACNA1H) and a glucose transporter (GLUT1) residing in the plasma membrane and an inositol 1,4,5-trisphosphate receptor (ITPR1) located mainly in the endoplasmic reticulum (ER) ( Figure 3C ). Second, all three mutations affect disordered regions exposed to the cytosol, which makes them accessible to cytosolic adaptor proteins that mediate clathrin recruitment. Third, all three mutations involve the change of a proline to a leucine residue and thereby result in the appearance of a novel dileucine motif (''LL'') in the IDR ( Figure 3D ). Such motifs are known to recruit clathrin to the plasma membrane or intracellular locations (Pandey, 2009) et al., 2016) , but variations of this theme are common (Kozik et al., 2010; Pandey, 2009; Staudt et al., 2017; Traub, 2009 ).
A Dileucine Motif Gain Causes Mislocalization of the Glucose Transporter GLUT1
To assess the functional significance of the dileucine motif gains and clathrin recruitment, we selected the P485L mutation in GLUT1/SLC2A1. This mutation causes GLUT1 deficiency syndrome (G1DS), a disorder characterized by seizures and intellectual disability with onset in early infancy (De Vivo et al., 1991; Leen et al., 2010; Pascual et al., 2008) . GLUT1 is mainly expressed in endothelial cells that form the blood-brain-barrier and in astrocytes, facilitating glucose entry into the brain. Pathogenic mutations in GLUT1 impair cerebral glucose flux, leading to permanent encephalopathy.
To determine the impact of the P485L mutation on the subcellular localization, we first generated stable inducible cell lines expressing epitope tagged full-length wild-type or mutant GLUT1. While the wild-type protein mainly localized to the plasma membrane, the P485L mutant displayed an intracellular pattern (Figure 4A) . Hence, the mutation indeed causes protein mislocalization. Colocalization experiments with several markers confirmed that mutated GLUT1 localizes to endocytic compartments (Figures 4B and S3) . To more systematically characterize the cellular compartment in which GLUT1_P485L resides, we used BioID as a proximity labeling method (Roux et al., 2012) (Table S4) . We performed this experiment in a comparative manner for both wild-type and mutant GLUT1 using SILAC-based quantification (see STAR Methods). Mutated GLUT1 colocalized with proteins involved in membrane trafficking, clathrin-mediated endocytosis, and post-Golgi trafficking ( Figure 4C ). In contrast, wild-type GLUT1 colocalized with plasma membrane-associated proteins.
Adaptor Proteins Bind to Mutant GLUT1 and Cause Cellular Mistrafficking
The BioID experiment identified several subunits of heterotetrameric vesicular transport adaptor proteins (APs). This finding is particularly relevant because AP-1, AP-2, and AP-3 directly bind to both dileucine motifs and clathrin to mediate cellular transport (Traub and Bonifacino, 2013) . Binding of AP complexes to the cargo triggers a conformational change, which opens up the AP complex. It now exposes a ''Clathrin box motif'' that leads to recruitment of clathrin, which begins to surround the emerging vesicle bud as a second protein layer.
All subunits of AP-1, AP-2, and AP-3 that we identified showed increased co-localization with mutated GLUT1 when compared to the wild-type in both the forward and reverse (that is, SILAC label swap) BioID experiment ( Figure 5A ). We therefore tested whether the cytosolic tail of GLUT1 can interact with APs in vitro and found that mutated, but not wild-type, GLUT1 pulled down both AP-1 and AP-2 ( Figure 5B ). Together, these results show that the mutation causes association of GLUT1 with APs, providing a molecular explanation for mistrafficking. Because we did not detect APs as hits in our original screen, we designed targeted assays against peptides from several APs based on their known fragmentation spectra (Zauber et al., 2018) . Repeating the peptide pull-downs for GLUT1, CACNA1H and ITPR1 with targeted proteomics as readout, confirmed that several APs preferentially interact with the mutated peptides ( Figure S4) .
APs localize to different intracellular compartments and mediate membrane trafficking in distinct pathways (Park and Guo, 2014) . For example, AP-2 mediates clathrin-dependent endocytosis at the plasma membrane (McMahon and Boucrot, 2011; Pandey, 2009; Staudt et al., 2017; Traub, 2009) . The interaction of GLUT1_P485L with AP-2 thus suggests that internalization of the protein from the plasma membrane contributes to its mislocalization. To test if mutant GLUT1 is taken up via endocytosis, we added fluorescently labeled transferrin to GLUT1 expressing cells. Mutant, but not wild-type, protein extensively colocalized with endocytosed transferrin (Figures 5C and 5D ). If the P485L mutation causes GLUT1 endocytosis via AP-2, inhibiting AP-2 function should restore the correct subcellular localization. We therefore used small interfering RNAs (siRNAs) to knock down AP-2 ( Figure 5E ). Consistent with our prediction, loss of AP-2 expression rescued the mislocalization of mutated GLUT1 ( Figure 5F ). We also tested the ability of stable cell lines inducibly expressing GLUT1 to take-up radiolabeled glucose. Cells expressing the mutated protein showed significantly increased glucose uptake when AP-2 was knocked down ( Figure 5G ).
GLUT1 P485L Mislocalizes in Patient-Derived Induced Pluripotent Stem Cells
The experiments described so far are based on in vitro assays or cell line models expressing tagged variants of GLUT1. We therefore sought to validate our findings by analyzing the behavior of endogenous GLUT1 in patient cells. To this end, we obtained fibroblasts from a GLUT1-deficient patient harboring the P485L mutation via a skin punch biopsy (see STAR Methods). Because fibroblasts do not express significant amounts of GLUT1, we reprogrammed them into induced pluripotent stem cells (iPSCs) by RNA-based transfer of pluripotency factors ( Figure 6A ). The clones obtained showed characteristic expression of pluripotency markers ( Figure S5 ). We then analyzed the subcellular distribution of GLUT1 in these cells. While GLUT1 was mainly localized in the plasma membrane of control iPSCs, patientderived cells showed characteristic intracellular accumulations ( Figure 6B ). Co-staining with a post-Golgi SNARE revealed extensive colocalization (Kreykenbohm et al., 2002) (Figures  6C and 6D ). Of note, the patient-derived iPSCs also showed GLUT1 signal at the plasma membrane. This is consistent with the fact that only one GLUT1 allele in the patient is affected (Leen et al., 2010; Pascual et al., 2008; Slaughter et al., 2009 (A) Confocal images of GLUT1 localization in HEK cells, stably expressing FLAG-GLUT1, reveal that the wild-type is localized mainly at the cell membrane while the P485L mutant is mislocalized to endocytic compartments. (green, FLAG-GLUT1; blue, DAPI). Scale bars, 10 mm.
(B) Colocalization analysis shows extensive colocalization of mutant, but not wild-type GLUT1 with markers of several endocytic compartments. Pearson's thresholded coefficients (as implemented in the Imaris software) were determined for GLUT1 variants with the indicated proteins. Data are represented as mean ± SD. See Figure S3 for example images. (C) Comparison of proteins colocalizing with wild-type and mutant GLUT1 by proximity labeling (BioID). The upper left panel shows SILAC log2 fold changes from two replicate experiments with swapped isotope labels. Blue and red labeled proteins are enriched by wild-type GLUT1 or mutant GLUT1, respectively. The ten most significant cellular component GO-terms reveal that mutated GLUT1 is involved in clathrin-dependent processes and endosomal trafficking. In contrast, wild-type GLUT1 colocalizes with plasma membrane-associated proteins. The lower panel is colored according to the top three enriched GO-terms and shows the variants typical subcellular compartments. Table S4 . Figure S4 . (B) P485L mutant but not wild-type Glut1 C-terminal tail interacts with AP-1 and AP-2. Tails were tagged with GST to pull-down interaction partners from mouse brain lysate. Talin is shown as a negative control and is not pulled down from either of the two variants. (C and D) Mutant but not wild-type GLUT1 extensively colocalizes with endocytosed transferrin. HEK cells stably expressing FLAG-GLUT1 are incubated with fluorescently labeled transferrin for 10 min before fixation. Scale bar, 10 mm (C). Data are represented as mean ± SD (D) . (E and F) Western blot against AP-2 a and m subunits shows downregulation after two rounds of siRNA transfection against AP-2 m. AP-2 knockdown leads to relocalization of GLUT1_P485L to the plasma membrane and hence rescue of the mutation phenotype. Scale bar, 10 mm.
GLUT1_P485L Localization at the Blood-Brain-Barrier Is Perturbed In Vivo
To study the P485L mutation in vivo, we used CRISPR/Cas9 to generate the corresponding mutant in the mouse ( Figure 6E ). Heterozygous mice were viable, fertile, and did not display any obvious phenotype. However, out of 6 heterozygous crossings, we failed to detect any born homozygous mutant pup. A detailed inspection of maternal delivery illustrated that homozygous mutant pups come to term but die immediately after birth and are removed from the litter by the dams. To histologically analyze GLUT1 distribution in the endothelial cells of the blood-brainbarrier, we dissected embryonic (E) day 14.5-15.5 mice and stained their cerebral cortex with antibodies against GLUT1. We co-stained with anti-ICAM2 to label the luminal plasma membrane and isolectin B4 (IB4) to label the entire endothelial plasma membrane. We observed an overall reduction in GLUT1 staining in heterozygous and homozygous animals with otherwise largely normal vascular morphology ( Figure 6F ). High resolution STED imaging revealed a strong reduction in the density of GLUT1 clusters in endothelial plasma membranes of homozygous mutant mice compared to wild-type littermates (Figures 6G and 6H) . Hence, the P485L mutation also reduces GLUT1 levels in the plasma membrane in vivo.
Gains in Dileucine Motifs as a General Disease Mechanism
We next investigated whether dileucine motif gains represent a more general disease mechanism. To test this, we conducted a search of missense mutations associated with disease that occur within disordered cytosolic regions of transmembrane proteins. We found four additional pathogenic dileucine motif gains in the Humsavar database ( Figure 7A ; Table S5 ). The same search in the ClinVar database returned four additional mutations. For example, two dileucine motif gains affect cytosolic regions of the cystic fibrosis transmembrane conductance regulator (CFTR) and cause cystic fibrosis ( Figure S6A ; Table S5 ). In total, 11 dileucine motif gains in 8 different proteins cause a wide range of diseases.
Because we focused our follow-up experiments on GLUT1, we cannot state with certainty that the other dileucine motif gains also cause protein mistrafficking. Alternatively, the mutations could cause disease by different mechanisms and might just create dileucine motifs as a by-product. If that was the case, dileucine motifs should be homogeneously distributed between disease-causing mutations and non-pathogenic polymorphisms. In contrast, if dileucine motif gains are responsible for pathogenesis, they would be predicted to occur more often in disease than in non-pathogenic variants. Moreover, pathogenic dileucine motif gains should be specific for cytosolic regions of transmembrane proteins because this is where they exert their function. To test these predictions, we compared the frequency of dileucine motif gains found in disease-causing mutations to their appearance in non-pathogenic polymorphisms (from Humsavar). A global survey of all disordered regions of the entire proteome revealed that dileucine motif gains occurred at about the same rate in disease and non-pathogenic variants (odds ratio [OR] = 0.81, p value = 0.319, two-sided Fisher's exact test). In the cytosolic tails of transmembrane proteins, however, we observed a 3.7-fold enrichment of dileucine motifs implicated in disease (OR = 3.7, p value = 0.017, two-sided Fisher's exact test, Figure 7B ). Disordered extracellular regions of transmembrane proteins do not show this enrichment. Performing the equivalent analysis with the ClinVar database yielded similar results ( Figure S6B ). We conclude that dileucine motif gains in disordered regions of the cytosolic segments of transmembrane proteins are significantly and specifically enriched in disease. To further assess the significance of this finding, we systematically searched within cytosolic regions of transmembrane proteins for all other annotated SLiMs contained in the ELM database (Dinkel et al., 2016) . Intriguingly, of all 263 SLiMs tested, the dileucine motif (LIG_diLeu_1) was the only significantly enriched motif in disease ( Figure 7C ).
Finally, to test if some of the additional dileucine motif gains can cause mistrafficking, we performed antibody feeding experiments. We created chimeric proteins consisting of the IL-2 receptor alpha chain (TAC) fused to mutated and wildtype cytosolic regions of the respective disease protein (see STAR Methods). Cells expressing these constructs are incubated with antibodies against the extracellular region of TAC and allowed to endocytose the chimeric proteins together with bound antibodies. A specific staining protocol is then used to exclusively detect internalized antibodies (Diril et al., 2009 ). We generated fusion proteins for GLUT1 (as positive control) and seven additional dileucine motif gains. Four of the seven mutations resulted in increased internalization relative to the corresponding wild-type sequences ( Figure 7D ). In addition, we observed mutant-specific interaction of AP-1 and/or AP-2 for several selected cytosolic regions in in vitro interaction assays ( Figure S6D ). Collectively, these results indicate that several additional pathogenic dileucine motif gains cause protein mistrafficking.
DISCUSSION
Understanding the functional relevance of protein variants is a major challenge in the era of personal genomics-especially for missense mutations in disordered regions. Our proteomic screen provides a first systematic experimental analysis of how mutations in disordered regions affect protein-protein interactions. Our results show that the method can (1) capture known interactions, (2) detect how mutations in SLiMs affect binding of cognate domains, and (3) provide mechanistic insights into pathogenesis. The peptide-based method is especially useful for mutations in proteins that are otherwise difficult to study, (G) AP-2 knock down leads to rescue of glucose uptake in GLUT1_P485L expressing cells. GLUT1 expression was induced by doxycycline, cytochalasin B inhibition was used as control. % glucose uptake is relative to GLUT1 wild-type, +doxycycline, Àcytochalasin B. Mean values of technical triplicates from three independent experiments are shown. We only compared glucose uptake within and not between cell lines to avoid possible differences between clones. Error bars, SEM. **p value < 0.01 from a paired, one-sided t test.
Pearson's correlation coefficient 
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(legend continued on next page)
such as large transmembrane proteins. Nevertheless, it is also important to consider the intrinsic limitations of the approach. Most importantly, in vitro pull-downs do not necessarily reflect physiological interactions in vivo. For example, artifactual bind-(E) A mouse carrying the GLUT1 P485L mutation was created by CRISPR/Cas9-targeted method. PAM sequence and gRNA are marked in targeted region of SLC2A1 (GLUT1 gene). Sanger sequencing confirmed insertion of mutation (chromatogram: A = green, T = red, C = blue, G = black).
(F) Immunohistological analyses of cortical slices of wild-type, heterozygous, and homozygous GLUT1 mutant mice using antibodies against GLUT1 (red) and DAPI (blue) as counterstain (left panels); a higher magnification of a vessel stained by antibodies against GLUT1 (red), IB4 (green), and ICAM2 (blue) is shown in the right panels.
(G) Representative STED images of transverse cross-sections through brain vessels of wild-type (+/+), heterozygous (+/P485L) and homozygous (P485L/P485L) mutant mice stained with isolectin B4 and antibodies against GLUT1 and ICAM2. Insets show a fragment of abluminal membrane (IB4 positive, ICAM2 negative) indicated with a black box. Scale bars, 2 mm (main panels); 0.25 mm (insets).
(H) Quantification of GLUT1 signal relative to IB4 signal in vessel membranes (n, number of vessels per genotype; N, number of animals per genotype). Boxplot central line indicates the median, the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively. n.s. Figure S6 and Table S6. ing can occur when combining peptides and proteins that never meet each other in the cell (Gibson et al., 2015) . Moreover, taking IDRs out of the context of the fulllength protein and immobilizing them as short peptides can affect interactions. Finally, amino acids within IDRs often carry posttranslational modifications-a possibility that we did not consider here. In the future, it will be interesting to include modified peptides, especially because mutations often affect modification sites (Narayan et al., 2016; Radivojac et al., 2008) . Our screen revealed that three mutations in cytosolic tails of transmembrane proteins create dileucine motifs and lead to increased binding of clathrin. Follow-up experiments demonstrated that the dileucine motif gain in GLUT1 causes mislocalization from the plasma membrane to endocytic compartments. We also observed that mutated GLUT1 recruits several adaptor proteins, thus providing a direct link between the motif gain, clathrin recruitment, and GLUT1 mistrafficking. Knocking down AP-2 rescued mislocalization of mutated GLUT1 and restored glucose transport. This finding shows that the aberrant trafficking is-at least partially-due to increased endocytosis. However, it should be kept in mind that AP-1 and AP-3 mediate other trafficking events such as transport between endosomes and the trans-Golgi network or transport to lysosomes (Dell'Angelica, 2009; Park and Guo, 2014) . The observation that mutated GLUT1 also interacts with these APs therefore suggests that other trafficking events may also be perturbed.
The finding that pathogenic mutations in cytosolic tails of other transmembrane proteins also create dileucine motifs is particularly intriguing. We term diseases caused by such motif gains ''dileucineopathies''. Whether the other dileucine motif gains cause protein mislocalization similar to GLUT1 remains to be investigated. The observation that these mutations are significantly and specifically enriched in cytosolic domains suggests that at least some of them are functional. Also, we have found that four out of seven tested mutations increase internalization of chimeric proteins in antibody feeding experiments. This further supports the view that at least some pathogenic dileucine motif gains cause disease by inducing protein mistrafficking. However, more detailed follow-up experiments are required to test this hypothesis for individual mutations. It is also interesting to note that a pathogenic mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) has been reported to generate a tyrosine-based internalization motif (Silvis et al., 2003) .
Why are dileucine-motif gains a recurrent cause of disease? We think this is due to a combination of several factors: First, dileucine motifs are not very complex and can thus easily arise by chance. Second, proline codons can mutate to leucine codons by changing a single nucleotide. Third, proline is overrepresented in IDRs, which are also the sites where the motif needs to be located in order to be functional. Because the genetic cause of many diseases has not yet been identified (Boycott et al., 2013) , we expect that more pathogenic dileucine motif gains will soon emerge. Knowing that such gains can be pathogenic will make it easier to classify them as disease-causing among the many variants present in the human population (Cooper and Shendure, 2011) . The observation that GLUT1 mislocalization and glucose transport can be rescued suggests that pathogenic dileucine motif gains may be druggable. Whether patients with ''dileucineopathies'' might benefit from inhibiting specific clathrin-dependent trafficking events remains to be investigated.
Bioinformatic studies have established that pathogenic mutations in disordered regions often affect SLiMs (Narayan et al., 2016; Radivojac et al., 2008; Uyar et al., 2014) . However, whether these predicted motif changes really affect proteinprotein interactions has not yet been investigated systematically. Moreover, many motifs have not yet been defined and thus escape computational predictions (Tompa et al., 2014) . The biochemical approach presented here provides a useful complementary strategy to computational studies. Key advantages of our setup are its scalability (by using synthetic peptides) and specificity (by employing two quantitative filters). While we focused on neurological disorders here, the approach can also be applied to other types of Mendelian disorders, somatic mutations in cancer and also to non-pathogenic polymorphisms.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines SH-SY5Y and T-REx-293 cells were cultured under standard cell culture conditions. In brief, cells were cultured in DMEM (Life Technologies) complemented with 10% fetal calf serum (Pan-Biotech). Cells used for SILAC based experiments were cultured in SILAC DMEM (Life Technologies) complemented with glutamine (Glutamax, Life Technologies), Pyruvate (Life Technologies), non-essential amino acids (Life Technologies) and 10% dialyzed fetal calf serum (Pan-Biotech). The SILAC DMEM was supplemented with standard L-arginine (Arg0, Sigma-Aldrich) and L-lysine (Lys0, Sigma-Aldrich) (''light'') as in Schwanhä usser et al. (2011) . Alternatively, Arg6 and Lys4 (''medium-heavy'') or Arg10 and Lys8 (''heavy'') were added in place of their light counterparts. Cells were cultured at 37 C and 5% CO 2 .
Flp-In T-Rex GLUT1
We purchased SLC2A1 ( SLC2A1 and SLC2A1 mutant have been further cloned into a destination vector with a N-terminal BirA-FLAG Tag (pDESTpcDNA5-BirA-FLAG N-term (Couzens et al., 2013)) with Gateway cloning strategy (Thermo Fisher Scientific). HEK293 Flp-In T-Rex cells (Invitrogen) that exhibit tetracycline-inducible expression of BirA-FLAG-GLUT1 or BirA-FLAG-GLUT1_P485L were generated using the Flp-In system developed by Life Technologies according to the manufacturer's protocol.
Patient-derived iPSCs
Fibroblasts were obtained from a GLUT1 deficient patient with the P485L mutation. The voluntary informed consent process was documented in writing as approved in advance by the University of Texas Southwestern Medical Center Institutional Review Board. This included information regarding the de-identification of the sample and the adherence to HIPAA regulations.
A 4 mm single-use, sterile skin punch was applied to the lateral surface of the left shoulder after the skin had been cleansed with iodine solution in aseptic fashion followed by injection of 0.5 mL of 1% unbuffered lidocaine with a vasoconstrictor. Prilocaine and lidocaine cream had been previously applied to the area. The punch was advanced by rotation under pressure and the explant was severed from its base and harvested in culture medium containing complete DMEM plus 20% fetal bovine serum and placed on ice until the explant was divided for culture the same day. The explant was divided into 12-15 evenly sized pieces and each piece maintained in a 10 cm dish at 37 C until fibroblast confluence was reached. The cells were then treated with trypsin and passaged into a T-25 flask for further expansion. Fibroblasts were grown to approximately 50% confluence in the T-25 flask. They were then suspended with trypsin and frozen over dry ice in complete DMEM medium with 10% DMSO at a density of 10 6 cells/mL per vial prior to storage and shipment on dry ice.
The patient fibroblast were reprogrammed using the mRNA reprogramming kit ReproRNA-OKSGM from Stem Cell Technologies according to the instructions. In brief, 1x 10 5 fibroblast cells were plated on Geltrex coated 6-well plate using regular DMEM media with 10% FBS. The day after the cells were transfected with the ReproRNA-OKSGM construct using the ReproRNA transfection reagents and growth Media with B18R. The next 5 days the growth media was changed every day and supplemented with B18R and 0.8 mg/mL Puromycin. After 8 days the growth media was exchanged by ReproTeSR and first colonies appeared after 14 days. In total 5 clones were picked and established using mTESR-1 media. As a control for the experiments the following fibroblasts (NHDF-Ad-Der Fibroblasts, C-2511, LONZA) were reprogrammed using the Epi5 Episomal iPSC Reprogramming Kit from The iPSCs used for the experiments were characterized using the PSC 4-Marker immunocytochemistry kit from Thermo Fisher Scientific following the instructions of the protocol. In addition to the 4 markers (OCT4, SOX2, TRA-1-60 and SSEA4) included in the kit, the expression of another pluripotency marker NANOG (Nanog PA1-097, Thermo Fisher Scientific) was analyzed.
Human iPSC cultures were maintained on plates coated with hESC-Qualified Matrigel (Corning) in mTESR-1 medium (Stem Cell Technologies) following the manufacturer's instruction. All cells were cultured at 37 C in humidified atmosphere containing 5% O 2 and 5% CO 2 . Cells were passaged using StemPro Accutase (Thermo Fisher) and replated in mTESR-1 medium with the addition of 10 mM ROCK inhibitor Y-27632 (LC Laboratories).
Animal model GLUT1 P485L mice were produced by microinjection of C57BL/6N zygotes with Cas9 protein (IDT), synthetic guide RNA (IDT) (5 0 GAGGAGCTCTTCCACCCTCT3 0 ) and a mutagenic single stranded deoxyoligonucleotide (IDT) (5 0 TAGCTGCCTGTGCTCCAG AGAGATCCTTGGGCTGCAGGGAGCAGGCCGGGCTGGGTGTGGGGCTCCTCACACTTGGGAGTCCGCCCCCAacaaGTGGAAGA GCTCCTCGGGTGTCTTGTCACTTTGG3 0 ) as recombination template, as described (Wefers et al., 2017) . Reagents were diluted in microinjection buffer (10 mM Tris, 0.1 mM EDTA, pH 7.2), filtrated through a centrifugal filter (Millipore, UFC30LG25) and stored in single use aliquots at À80 C. For microinjections, zygotes were obtained by mating of C57BL/6N males with superovulated C57BL/6N females (Charles River, Sulzbach, Germany). Zygotes were injected into one pronucleus following standard procedures (Ittner and Gö tz, 2007) . Injected zygotes were transferred into pseudo-pregnant NMRI female mice to obtain live pups. All mice showed normal development and appeared healthy. Mice were handled according to institutional guidelines under experimentation license no. G0162/12 approved by the Landesamt fü r Gesundheit und Soziales (Berlin, Germany) and housed in standard cages in a specific pathogen-free facility on a 12 h light/dark cycle with ad libitum access to food and water.
METHOD DETAILS
Peptide-protein interaction screen This dataset consists of experimentally validated missense mutations that contribute to inherited diseases. Inherited disease mutations were downloaded from UniProt (https://www.uniprot.org/docs/humsavar.txt, Release: 2015_07 of 24-Jun-2015) (Famiglietti et al., 2014) . Only mutations that were associated to 'Disease' were kept. 'Unclassified' mutations or 'Polymorphisms' were excluded. The 26,649 disease mutations were further filtered by applying a disorder cut-off. Disorder tendencies of 15 amino acids (AAs) long peptides, with the AA mutated in disease if possible located at position eight, were predicted using IUPred (Dosztá nyi et al., 2005) using the 'SHORT' profile considering sequential neighborhood of 25 residues. IUPred disorder scores above 0.5 denote regions of the proteins that have 95% likelihood to be disordered. For filtering, the mean disorder score for all 15 AA as well as the mutation position were required to be > 0.5. This resulted in 1,878 disease mutations in disordered regions. Next we assigned disease classes to 3,119 different diseases included in the humsavar database by combining a manual approach with automatic annotation with the Human Phenotype Ontology database, HPO (Kö hler et al., 2017) . We selected 305 mutations causing neurological diseases. After manual inspection, we remained with 128 mutations causing 124 distinct neurological diseases that were used for the peptide-protein interaction screen.
Experimental setup
Peptides of 15 AAs, in total 128 wild-type peptides and 128 related peptides containing the disease causing mutation (256 peptides) plus one control peptide pair were synthesized in situ on cellulose membrane using PepTrack techniques (JPT Peptide Technologies, Berlin, Germany). Two of those peptide filters were moistened in cell lysis buffer [50 mM HEPES pH 7.6 at 4 C, 150 mM NaCl, 1 mM EGTA, 1 mM MgCl2, 10% Glycerol, 0.5% Nonidet P-40, 0.05% SDS and 0.25% sodium deoxycholate, supplemented with protease inhibitor (Roche) and benzonase (Merck)]. In order to reduce nonspecific binding the membrane was incubated with 1 mg/mL yeast t-RNA (Invitrogen) for 10 min and then washed twice with cell lysis buffer without detergents. The entire peptide libraries were incubated with 15 mL of light or heavy SILAC labeled cell lysate (5 mg/mL) from SH-SY5Y cells for 2 h. Membranes were washed three times and air-dried. Sample preparation for mass spectrometric analysis Single spots were punched out from cellulose membrane with a 2 mm diameter ear punch (Carl Roth) and SILAC pairs were placed together in a 96-well plate (Thermo Fisher Scientific) prepared with 30 ml of denaturation buffer [6 M urea (Sigma-Aldrich), 2 M thiourea (Sigma-Aldrich), 10 mM HEPES, pH 8]. Samples were reduced by incubating with 10 ml of 3.3 mM DTT (Sigma-Aldrich) for 30 min at RT, followed by an alkylation step using 10 ml of 18.3 mM iodoacetamide (IAA) (Sigma-Aldrich) for 60 min at RT. The samples were first digested using 1 mg endopeptidase LysC (Wako, Osaka, Japan) for 4 h. The samples were diluted by adding 100 ml of 50 mM ammonium bicarbonate (pH = 8.5), and finally digested with 1 mg trypsin (Promega) for 16 h. The digestion was stopped by acidifying each sample to pH < 2.5 by adding 10% trifluoroacetic acid solution. The peptide extracts were purified and stored on stage tips according to Rappsilber et al. (2003) .
LC-MS/MS analysis
Peptides were eluted using Buffer B (80% Acetonitrile and 0.1% formic acid) and organic solvent was evaporated using a speedvac (Eppendorf). Samples were diluted in Buffer A (5% acetonitrile and 0.1% formic acid). Peptides were separated on a reversed-phase column with 45 min gradient with a 250 nl/min flow rate of increasing Buffer B concentration on a High Performance Liquid Chromatography (HPLC) system (Thermo Fisher Scientific). Peptides were ionized using an electrospray ionization (ESI) source (Thermo Fisher Scientific) and analyzed on a Q-exactive plus Orbitrap instrument (Thermo FisherScientific). Dynamic exclusion for selected precursor ions was 30 s. The mass spectrometer was run in data dependent mode selecting the top 10 most intense ions in the MS full scans, selecting ions from 300 to 1700 m/z (Orbitrap resolution: 70,000; target value: 1,000,000 ions; maximum injection time of 120 ms). The resulting MS/MS spectra from the Orbitrap had a resolution of 17,500 after a maximum ion collection time of 60 ms with a target of reaching 100,000 ions.
Data analysis
The resulting raw files were analyzed using MaxQuant software version 1.5.2.8 (Cox and Mann, 2008) . Default settings were kept except that 'match between runs' and 're-quantify' was turned on. Lys8 and Arg10 were set as labels and oxidation of methionines and N-terminal acetylation were defined as variable modifications. Carbamidomethyl of cysteines was set as fixed modification. The in silico digests of the human Uniprot database (2015-12), a FASTA file containing all peptides used for pull-down and a database containing common contaminants were done with Trypsin/P. The false discovery rate was set to 1% at both the peptide and protein level and was assessed by in parallel searching a database containing the reversed sequences from the Uniprot database. Following statistics and figures were done using R (R version 3.2.1, RStudio Version 1.0.143). The resulting text files were filtered to exclude reverse database hits, potential contaminants, and proteins only identified by site. We imputed missing LFQ-intensity values with random noise simulating the detection limit of the mass spectrometer (Keilhauer et al., 2015) . To this end, imputed values are taken from a log normal distribution with 0.25 3 the standard deviation of the measured, logarithmized values, down-shifted by 1.8 standard deviations. In this way, we obtained a distribution of quantitative values for each protein across samples. For determination of specific interactions, two replicated pull-downs for the same peptide were tested against all other pull-downs, excluding the corresponding variant peptide, by the nonparametric Mann-Whitney U test. Resulting p values and fold-changes (log2 space) have been plotted as volcano plots to determine cut-offs. We used an approach that uses a graphical formula to combination a fold-change and p value cut-off (Keilhauer et al., 2015) : Àlog10ðpÞ R c jx j Àx0 with x: enrichment factor of a protein, p: p value of the Mann-Whitney U test calculated from replicates, x 0 : fixed minimum enrichment, c: curvature parameter. The curvature parameter c determines the maximum acceptable p value for a given enrichment x.
The parameters c and x 0 can be optimized based on prior knowledge of known true and false positives (Keilhauer et al., 2015; Schulze and Mann, 2004) . Here, cut-offs were chosen according to known interaction partners of the SOS1 control peptide (Keilhauer et al., 2015) . This resulted in x 0 = 0, c = 8. This cut-off was applied to all other pull-downs to separate specific binders from background. SILAC ratios were normalized by subtracting the median SILAC ratio of every experiment from all SILAC ratios in that experiment. To define interaction partners that bind differentially to wild-type and mutant peptide, a SILAC cut-off has been defined. For wild-type specific interaction partners, the mean log2 SILAC ratio of the two replicates needed to be > 1 and none of the two ratios < 0 (mutant specific mean log2 SILAC ratio < À1 and none of the two ratios > 0). Resulting figures were modified in Inkscape (0.91).
PRM
Experimental procedure was identical to general peptide-protein interaction screen. Only peptide variants from GLUT1_P485L, ITPR1_P1059L, CACNA1H_P648L and CACNA1H_A748V (control peptide) have been used for experiment.
LC-MS/MS analysis
Peptides were separated by reverse phase chromatography on an effective 150 min gradient (0, 2, 100, 30, 15, 1 and 5 min with 2, 4, 20, 30, 60, 90 and 90% of buffer B with 90% acetonitrile) and analyzed on a Q-Exactive HFx (Thermo Fisher Scientific). The PRM settings were: 30,000 resolution; 5e5 AGC target; 1.6 m/z isolation window; 60 ms max ion injection time. The inclusion list for the PRM method was generated using Picky (Zauber et al., 2018) with SILAC option enabled and a retention time window of 30 min. Predicted retention-times were calibrated in Picky with a complex sample of 100 ng Pierce HeLa Protein standard (Thermo Fisher Scientific) immediately before the PRM measurements.
Analysis of PRM data
Traces of all fragments from precursors in the spectral library (as exported from picky) were extracted from all rawfiles using the Thermo MSFileReader and the MSFileReader.py bindings written by Francois Allen. For each light or heavy scan the normalized spectral contrast angle (SCA) was calculated (Toprak et al., 2014) . Peaks were manually selected and required a SCA > 0.4 and Fragment Matches > 4 in the light or heavy channel. Further Peaks needed to be within a similar retention time range across all different measurements. Ratios for each fragment using the maximum intensity of each peak were calculated. The median log2 transformed ratio (log2FC) for each peptide in each raw-file was calculated from selected fragment ratios: The five highest abundant fragments were selected from the peak with the highest detected SCA. Peptide log2FC were plotted as boxplot distributions in a protein centric manner across the different experiments ( Figure S4A ).
BioID
Medium-heavy and heavy labeled T-REx-293 cells have been induced for 24 h with 0.1 mg/mL Doxycycline to induce expression of GLUT1 (wild-type, wt) or GLUT1_P485L (mutant, mut). Light labeled cell lines from both GLUT1 and GLUT1_P485L have been left uninduced and served as a control for background binding. SILAC labeling allowed for quantitative comparison of proteins that have been proximity labeled by the transiently expressed constructs (Forward experiment, B_1: Light -Control, Medium-heavy -wt, Heavy -mut; Label swap experiment, B_2: Light -Control, Medium-heavy -mut, Heavy -wt). During the induction period all cell lines have been incubated for 24 h in cell culture medium containing biotin. BioID experiment has been performed essentially as in Couzens et al. (2013) , with minor adaptations.
Mass spec setup and analysis was done similarly as to samples from peptide pull-downs, but on bead digested peptides were separated on a 2,000 mm monolithic column with a 100 mm inner diameter filled with C18 material that was kindly provided by Yasushi Ishihama (Kyoto University) using a 4 h linear gradient with a 300 nl/min flow rate of increasing Buffer B concentration on a High Performance Liquid Chromatography (HPLC) system (Thermo Fisher Scientific). The resulting raw files were analyzed using MaxQuant software version 1.5.2.8 (Cox and Mann, 2008) . Default settings were kept except that 'match between runs' and 're-quantify' was turned on. Lys4 and Arg6 or Lys8 and Arg10 were set as labels and oxidation of methionines and N-terminal acetylation were defined as variable modifications. Carbamidomethylation of cysteines was set as fixed modification. The in silico digests of the human Uniprot database (2015-12), a fasta file containing the sequence of BirA-FLAG-GLUT1 and a database containing common contaminants were done with Trypsin/P. The false discovery rate was set to 1% at both the peptide and protein level and was assessed by in parallel searching a database containing the reversed sequences from the Uniprot database.
Biotinylated proteins with a wild-type to mutant enrichment ratio (log2FC) > 1 or < À1 have been considered as significant. These proteins have been analyzed for gene ontology enrichment of cellular components with http://metascape.org (Tripathi et al., 2015) . FLAG-GLUT1 localization HEK293 Flp-In T-Rex cells with BirA-FLAG-GLUT1 or BirA-FLAG-GLUT1_P485L have been seeded on coverslips coated with poly-L-lysine (Sigma-Aldrich). After induction for 24 h in doxycycline (0.1 mg/mL) containing media, cells were fixed with 4% PFA (paraformaldehyde). Standard procedures were used for immunostaining. Cells have been stained against FLAG 1:200 (F1804, Sigma-Aldrich). Nucleus has been stained with DAPI (Sigma-Aldrich). FLAG staining was accompanied by staining to one of the following endosomal markers and with the following dilutions: anti-EEA1 (Cell Signaling Technology, 1:100); anti-Rab4 (Cell Signaling Technology, 1:100); anti-Rab9 (Cell Signaling Technology, 1:100); anti-LAMP1 (Cell Signaling Technology, 1:100). Mouse anti-FLAG staining was substituted by rabbit anti-GLUT1 (Merck Millipore, 1:500) to costain mouse monoclonal antibodies: anti-VTI1A (BD Biosciences, 1:100); anti-VTI1B (BD Biosciences, 1:100). Secondary antibodies all come from Invitrogen. For colocalization analysis three z stacks of 5-10 cells each have been quantified for each marker with Imaris v8.4.1 (see ''QUANTIFICATION AND STATISTICAL ANALYSIS'' for details).
Transferrin uptake
Essentially as in ''FLAG-GLUT1 localization.'' Additionally, after 24 h cells were serum-starved for 1 h and used for Transferrin (Tf) uptake. For Tf uptake, cells were treated with 10 mg mL À1 Tf-Alexa568 (Life Technologies) for 10 min at 37 C. For colocalization analysis three z stacks of more than 15 cells each have been quantified with Imaris v8.4.1 (see ''QUANTIFICATION AND STATISTICAL ANALYSIS'' for details).
FLAG-GLUT1 localization under AP-2 m knockdown
To rescue the GLUT1_P485L phenotype, clathrin mediated endocytosis (CME) has been inhibited by knocking down AP-2 m and hence the adaptor complex responsible for recognition of cargo for CME.
On day 1, cells were seeded in 6-well plates. On day 2, cells were transfected with 25 nM final siRNA concentration (AP-2 m: ON-TARGETplus Human AP2M1 (Dharmacon) and non-target: ON-TARGETplus Non-targeting Pool (Dharmacon)) according to DharmaFECT (Dharmacon) transfection protocol. 24 h after the transfection, medium was replaced with complete medium to reduce cytotoxicity and incubated for another 24 h. On day 4, siRNA transfection was repeated as described for day 2. On day 5, cells have been seeded in a 24-well plate onto coverslips coated with poly-L-lysine (Sigma-Aldrich) for microscopy and into a 6-well plate for western blot analysis. Doxycycline (0.1 mg/mL) has been added to the medium to induce expression of the GLUT1 constructs. After induction for 48 h, cells in 24-well plates were fixed with 4% PFA. Standard procedures were used for immunostaining. Cells were stained with rabbit polyclonal GLUT1 antibody 1:200 (Merck Millipore) and co-stained with mouse monoclonal anti-alpha adaptin antibody [AP6] 1:200 (Abcam). Secondary antibodies with Alexa fluorophores have all been purchased from Invitrogen. Nucleus has been stained with DAPI (Sigma-Aldrich).
Lysate from cells in 6-well plates has been used for western blotting, a and m2 subunits of AP-2 were detected using mouse monoclonal antibodies from Thermo Fisher Scientific and BD transduction, respectively. Profilin 1 was stained as a loading control with polyclonal rabbit antibody from CST. Horseradish peroxidase coupled secondary antibodies were purchased from GE Healthcare. Proteins were detected with chemiluminescence substrate (Perkin Elmer) on a ChemiDoc MP Imaging System (Bio-Rad) and quantified with Image Lab 5.2.1.
Antibody feeding assay
An antibody feeding assay was used to study the gain of endocytosis by gain of dileucine motifs. For antibody internalization assay, genes and cytoplasmic regions were chosen according to the following criteria: All 11 disease mutations from Humsavar and Clinvar ('Pathogenic' or 'Conflicting interpretations of pathogenicity', in case 'pathogenic' or likely pathogenic was included in the different interpretations) that lead to a gain of a dileucine motif have been considered. All regions ± 7 AAs of the mutation have been analyzed according to Eukaryotic Linear Motif (ELM) database (Dinkel et al., 2016) . CACNA1H_P618L and RET_P1039L were not considered for the assay since wild-type variants of the peptides already harbor trafficking motifs. For GLUT1_P485L the whole cytoplasmic C terminus was amplified via PCR adding EcoRV 5 0 and NotI 3 0 . All other seven constructs were generated by inserting the region surrounding the mutation position with Q5â Site-Directed Mutagenesis Kit (NEB) resulting in a 15 AA insert (we were not able to generate a construct for CACNA1H_P648L). Chimeras consisting of one of the cytoplasmic regions and the human TAC antigen (interleukin-2 receptor a chain, CD25) were constructed based on a TAC construct (Diril et al., 2009 ). HeLa cells were transiently transfected with the TAC chimera constructs using jetPRIME (Polyplus-transfection). Two days after transfection, cells were labeled with anti-TAC IgG (Santa Cruz Biotechnology) (1: 1000 diluted in Opti-MEM; Invitrogen) for 30 min at 4 C. After one change of medium (to Opti-MEM at 37 C), plasma membrane antigens were allowed to internalize for 30 min at 37 C. The cells were then fixed with 4% paraformaldehyde (Sigma-Aldrich) for 10 min on ice, and surface-bound TAC antibody was blocked using goat anti-mouse serum [goat anti-mouse IgG (Thermo Fisher Scientific at a 1: 5 dilution in goat serum dilution buffer, consisting of 30% normal goat serum (Sigma-Aldrich), 450 mm NaCl in 20mM sodium phosphate buffer pH 7.4] for 2 h at room temperature. Cells were permeabilized and blocked with goat serum dilution buffer containing 0.2% saponin for 10 min. For detection of internalized TAC antibody, a goat anti-mouse Alexa Fluor 488-conjugated IgG (Invitrogen) was added for 1 h. Cells were then washed three times for 10 min each with sodium phosphate buffer containing 0.02% saponin. For total TAC staining, the specimens were incubated for 1 h with TAC antibody diluted 1: 1000. As secondary antibody, an Alexa Fluor 594-conjugated goat anti-mouse IgG (Invitrogen) was added for 30 min, and nuclei were stained using DAPI (Sigma-Aldrich). Cells were washed, and coverslips were mounted in ProLongâ Gold antifade reagent (Invitrogen). For imaging, cells with positive signal in the 594 channel were chosen. All cells in Figure 7D are positive for total TAC staining (594). We have seen that the level of internalised TAC chimera (488) does not correlate with the amount of total TAC staining (594), between samples and in the same sample, and hence we have decided to exclude this channel from visualization.
GLUT1 localization in iPSCs
Human iPSCs were seeded on coverslips coated with hESC-Qualified Matrigel (Corning). Cells were fixed with 4% PFA, stained with rabbit polyclonal GLUT1 antibody 1:200 (Merck Millipore) and costained with mouse monoclonal VTI1a antibody 1:100 (BD Biosciences). Secondary antibodies with Alexa fluorophores have all been purchased from Invitrogen.
Fluorescence microscopy from cell culture Images from FLAG-GLUT1 localization were acquired by Leica DMI6600 confocal laser scanning microscope with an HCX PL APO 63.0/1.40 oil objective. Transferrin uptake, GLUT1-localization under AP-2 m knockdown, antibody feeding assay and GLUT1 in iPSCs were acquired by a Zeiss LSM 700 confocal laser scanning microscope with an EC Plan-Neofluar/NA1.3 40x oil objective or a EC Plan-Apochromat/NA1.4 63x oil objective. Images were further processed with Fiji (Schindelin et al., 2012) . For colocalization analysis see ''QUANTIFICATION AND STATISTICAL ANALYSIS.'' Immunofluorescence in mouse tissue E14-E15.5 embryos were obtained by Caesarian section from pregnant dam on day 14-15.5 post-coitus. Whole-mount embryos were dissected in ice-cold phosphate buffer and fixed for 2 h with a solution of 4% PFA in ice-cold phosphate buffer and cryoprotected overnight in 30% sucrose in phosphate buffer at 4 C. Whole embryo heads were sectioned in a horizontal plane using a cryostat to obtain 12-16 mm sections. Sample preparation for confocal microscopy Essentially as in Herná ndez-Miranda et al. (2011) . Brain sections were incubated in blocking buffer 1 (5% horse serum and 0.1% Triton X-100 made in phosphate buffer) for 1 h at room temperature. Then, sections were incubated overnight in blocking buffer 1 containing the following antibodies: rabbit anti-GLUT1 (1:200; Merck Millipore #07-1401), rat anti-ICAM2 (1:100; BD Biosciences #553326) and Isolectin GS-IB4 Alexa Fluor 488 conjugate (1:100, Thermo Fisher Scientific #I21411) at 4 C. Next, sections were washed three times in ice-cold phosphate buffer and incubated for 3 h in blocking buffer 1 containing Cy3 horse anti-rabbit (1:500; Jackson Lab), Cy5 horse anti-rat (1:500; Jackson Lab) and DAPI at room temperature. Fluorescence was imaged on a Zeiss LSM 700 (Jena, Germany) confocal microscope in a non-blind manner. Sample preparation for STED microscopy Sections were washed twice for 5 min with PBS to remove the embedding resin and incubated in 0.2% Triton X-100 in blocking buffer 2 (1% bovine serum albumin, 1% fetal calf serum in PBS) for 1 h at room temperature. Samples were incubated with primary antibodies anti-GLUT1 (rabbit anti-human, Merck Millipore #07-1401) and anti-ICAM2 (rat anti-mouse CD102, BD Biosciences #553326) at 1:100 dilution in blocking buffer 2 overnight at 4 C. Next, samples were washed three times for 5 minutes in PBS and incubated with STAR Red goat anti-rabbit antibody (Abberior, #2-0012-011-9), Alexa Fluor 594 donkey anti-rat antibody (Thermo Fisher Scientific #A21209), and Isolectin GS-IB4 Alexa Fluor 488 conjugate (Thermo Fisher Scientific #I21411), all diluted at 1:500 in blocking buffer 2. Subsequently, samples were washed three times for 5 min in PBS and mounted in Abberior Mount Solid Antifade mounting reagent (Abberior, #4-0100-007-4) under #1.5 coverslips (22x50 mm, VWR #631-0138) and allowed to cure overnight at room temperature. STED imaging and image analysis IB4 and ICAM2 signals were used to assess the positions of luminal (IB4 and ICAM2 positive) and abluminal (IB4 positive, ICAM2 negative) vessel membranes. Cross-sections of vessels (10-20 per animal) were selected for imaging in areas where luminal and abluminal membranes were clearly distinguishable, typically in the vicinity of the endothelial cell nucleus.
STED images were acquired using Abberior STED microscope equipped with 640 nm, 561 nm and 485 nm pulsed excitation lasers, 775 nm and 595 nm pulsed depletion lasers, UPlanSApo 100x/1.40 Oil objective (Olympus), 509/22 (GFP), 605/50 (Cy3) and 685/70 (Cy5) bandpass emission filters and spatial light modulators for STED beam shaping and alignment. Emitted light was collected with avalanche photodiode detectors using 8 ns-wide detection time gates. 120 ms total pixel dwell time per channel was used. Cy3 and Cy5 channels were acquired by line switching followed by the acquisition of the GFP channel.
STED images in 488 nm and 640 nm channels were aligned using reference images of fluorescent beads (Tetraspeck, 100 nm, ThermoFisher Scientific #T7280). Centers of beads were determined by centroid fit and resulting positions were used as control points to calculate an affine transformation between the 488 nm and 640 nm channels.
To quantify the average amount of membrane-localized GLUT1 per vessel, a measurement area containing all pixels within 300 nm of manually segmented abluminal membrane was created. Luminal membranes were not included in the analysis due to frequent collapse of vessels during sample preparation. The ratio between mean GLUT1 and mean IB4 signal was used as a measure of GLUT1 to account for the amount of membrane in the measurement area, imaging depth and antibody penetration differences between samples. The ratio of GLUT1 to IB4 was further corrected using images of Tetraspeck beads for relative intensity fluctuations between Cy5 and GFP detection channels between imaging sessions. Statistical significance was assessed using unpaired Student's t tests of log2 transformed data. The analysis was performed using ImageJ and MATLAB 2015 (Mathworks, Inc) .
Radioactive glucose uptake under AP-2 m knockdown AP-2 knockdown was performed as described before (FLAG-GLUT1 localization under AP-2 m knockdown). Only that cells were seeded in triplicates in a 24-well plate without coverslips. Radioactive glucose uptake was performed mainly as in Shi and Kandror (2008) . Radioactive glucose cocktail was prepared by adding 10 mL of 3H-2-deoxy-D-glucose in ethanol:water solution (specific activity, 5-10 Ci (185-370 GBq) / mmol) (Perkin Elmer) to a 2.0-mL tube and left open for 5 min to evaporate ethanol. 1.6 mL of KRH(À) glucose and 16 mL of cold 2-DOG (100X) stock solution (100 mM 2-deoxy-D-glucose in KRH (À) glucose) (Sigma-Aldrich) were added to the tube. Cells in each well were rinsed with DMEM (without serum, SFM) warmed to 37 C and SFM was added to cells slowly and carefully by the side of the well in order to avoid detachment of cells. Cells were incubated with 0.5 mL of SFM (in case of +dox containing 1mg/ml doxycycline) per well for 2 h at 37 C. Cells in each well were washed twice with 2 mL of KRH(À) glucose buffer (121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO 4 , 0.33 mM CaCl 2 , 12 mM HEPES, pH 7.4) at 37 C. 225ml of KRH(-) containing 25 mM final Cytochalasin B (dissolved in DMSO) or 0.5% DMSO were added to each well. Immediately after, 25 mL of radioactive glucose cocktail was added to all wells. Samples were incubated at 37 C for 1 h and then transferred on ice. Radioactive glucose cocktail was aspirated, and ice-cold KRH (+) glucose (121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO 4 0.33 mM CaCl 2 :12 mM HEPES, 25 mM D-(+)-Glucose, pH 7.4.) was added to terminate the reaction. Cells were washed once more with ice-cold KRH(+) glucose. Plate was transferred to room temperature, and 400 mL of 0.1% SDS in KRH (À) glucose were added to each well, incubated at room temperature for 10 min, and thoroughly resuspend to homogeneity. 100 ml of the lysate was kept to measure protein concentration with DC protein assay kit I (BioRad). 300 mL of lysates were transferred in scintillation vials containing 4 mL of Rotiszint eco plus scintillation fluid (Carl Roth) and count in a Liquid Scintillation Analyzer (Tri-Carb 2800TR, PerkinElmer) for 1 min per vial. These numbers represent ''Counts in the samples.'' In parallel, 10 mL of the radioactive glucose cocktail were mixed with 290 mL of 0.1% SDS in KRH (À) glucose and this mixture was measured under the same conditions. This number represents ''Counts in the cocktail.'' The amount of intracellular 2-deoxyglucose was calculated using the following formula:
½Counts in the sample31000 ½Counts in the cocktail30:033½C3t pmol/mg 3 min, where [C] is protein concentration in mg/mL and t is the total time of incubation with radioactive glucose in min. All resulting values have been divided by the overall mean value from all wild-type GLUT1 (+ doxycycline, -cytochalasin B) and multiplied by 100 to receive relative values for glucose uptake (%). For test of statistical significance, the mean values of three technical replicates were calculated from three biological replicates. Statistical significance was determined with a paired, one-tailed t test. Depicted values are mean values over all replicates and error bars show standard error of mean (SEM) over all replicates.
GST pulldown assay GLUT1 cytoplasmic C-terminal tail was amplified from pDEST_pcDNA5_FLAG_BirA GLUT1 or GLUT1_P485L with Fw: tatatc GAATTCGTTCCTGAGACTAAAGGC, Rev: aacaatGCGGCCGCTTACACTTGGGAATCAGCC. This resulted in C-terminal tail amino acids 451-492 (UniProt P11166). Added EcoRI and NotI restriction sites have been used to insert the PCR product into pGEX6P1. Other cytoplasmic regions have been ordered as gBlocks Gene Fragments (IDT) from the region ± 20AA of the mutation position, with an additional 5 0 -EcoRV restriction site and 3 0 -Stop codon -NotI restriction site. After restriction, the gene fragments have been inserted into pGEX6P2.
Expression of GST-tagged proteins was induced for 5 h at 22 C by addition of isopropyl thio-b-d-galactoside (0.5 mM) to E.coli BL21 in 2X YT medium (0.8 OD). To lyse the cells, bacterial pellets were resuspended in PBS and left on ice for 15 min in presence of PMSF (1mM), cyanase (4U/mL) and lysozyme (1 mg$mLÀ1). Then, Triton X-100 was added to 0.5% and cells were sonicated for 2 min. Lysates were centrifuged for 15 min at 50 000 x g. 300 mL of glutathion-coupled beads were added to the supernatant and rotated end-over-end for 2 h at 4 C. Beads were washed three times with PBS / 0.1% Triton X-100 and once with PBS. Pulldown experiments were performed using mouse brain extracts. Mouse brains were homogenized in buffer (20 mM HEPES, 320 mM sucrose, pH 7.5) containing protease inhibitor cocktail (Sigma-Aldrich). The homogenate was centrifuged at 1000 x g for 10 min and the supernatant was supplemented with 1% Triton X-100, 50 mM KCl, 2mM MgCl 2 , and kept on ice for 10 min with occasional vortexing. The lysate was cleared by centrifugation at 17,000 x g for 15 min and at 178,000 x g for 15 min. The supernatant was recovered and used at a concentration of 7.5 mg protein/mL.
The pulldown experiments were performed using 85 mg of GST fusion proteins and 0.6 mL protein extract by end-over-end rotation for 3 h. The samples were washed four times with buffer containing 20 mM HEPES, 50 mM KCl, 2 mM MgCl2, Triton X-100 (1%) and once in the same buffer without detergent. Proteins were eluted from the beads twice with Laemmli buffer and analyzed by western blotting. The following antibodies and dilutions were used: mouse anti-talin 1:1000 (Sigma-Aldrich), mouse anti-g1 adaptin of AP-1 1:500 (BD Biosciences), mouse anti a-adaptin of AP-2 1:200 (BD Biosciences), horseradish peroxidase-conjugated goat anti-mouse 1:2000 or 1:5000 (Jackson labs).
Analysis of human missense variants and short linear motifs (SLiMs) SLiM regular expression patterns 262 annotated SLiM class definitions (regular expression patterns) were downloaded from the Eukaryotic Linear Motif (ELM) database (Dinkel et al., 2016) . In order to analyze dileucine motifs, an additional motif '.LL.' was added to this compilation and named 'LIG_diLeu_1' in order to conserve the naming convention followed by the ELM database. Pathogenic and non-pathogenic missense variants Humsavar dataset: For the analysis of the missense variants that lead to de novo SLiM instances in protein sequences Uniprot Humsavar dataset (version 12-Apr-2017) (Famiglietti et al., 2014) was downloaded and filtered for missense variants. Variants that are classified as 'Disease' or 'Polymorphism' in this dataset were selected.
ClinVar dataset: Clinically relevant genomic variation data annotated in the ClinVar database (Landrum et al., 2016) was downloaded from the ftp server (ftp.ncbi.nlm.nih.gov/pub/clinvar/tab_delimited/variant_summary.txt.gz) in tab-delimited format (latest update on 25th of March, 2017). The downloaded table was filtered for assembly version GRCh38, and variants of type 'single nucleotide variant' were kept. In order to integrate the ClinVar annotations with other kinds of annotations available from the Uniprot database, these nucleotide variants were translated to the Uniprot protein sequences to obtain single amino-acid substitutions using the Ensembl Variant Effect Predictor (version 82) (VEP) (McLaren et al., 2016) . The output of VEP tool was filtered to only keep missense variants such that the translated amino-acid substitution occurs at exactly the same amino-acid at the same position of the Uniprot sequence with the same gene name as those of the annotation in the ClinVar dataset ('Name' field). Thus, 98,219 unique single amino-acid substitutions (missense variants) from 4,298 Uniprot sequences were obtained. Variants primarily annotated with clinical significance levels 'Pathogenic', 'Pathogenic/Likely pathogenic', or 'Likely pathogenic' were grouped as 'Disease' variants, while variants annotated with 'Benign', 'Benign/Likely benign', or 'Likely benign' were grouped into the 'Polymorphism' variants.
Protein domains: PFAM domain annotations of proteins were downloaded from the PFAM database (ftp://ftp.ebi.ac.uk/pub/ databases/Pfam//releases/Pfam30.0/proteomes/9606.tsv.gz) (Finn et al., 2016) .
SLiM -PFAM associations: PFAM domains and SLiM classes that are known to interact were downloaded from the ELM database (http://elm.eu.org/interactiondomains).
Analysis of gain of SLiMs via missense variants in disordered regions
For each reviewed human protein from Uniprot (20, 191 proteins) , the disorder scores of each residue were calculated using IUPred (using the 'short' setting). Using a IUPred disorder score cut-off of 0.4, the missense variants in disordered regions were selected. The missense variants that overlap PFAM domains were further filtered out based on the PFAM domain annotations found in the protein feature files downloaded from Uniprot in GFF format (e.g., the link to the GFF file for GLUT1 is https://www.uniprot.org/uniprot/ P11166.gff). These protein feature files were also used to detect the transmembrane proteins and their cytoplasmic/extracellular regions. The missense variants in disordered regions and not overlapping any PFAM domains were further classified as variants from 1) the whole proteome, 2) the transmembrane proteins (only those that have annotation of at least one cytoplasmic domain or an extracellular domain, in total 3836 proteins), 3) the cytoplasmic domains of transmembrane proteins, and 4) extracellular domains of transmembrane proteins. For each of these classes, the number of disease-causing variants and the number of polymorphisms that lead to a gain of SLiMs was counted and a two-sided Fisher's Exact Test was applied to see if there is a statistically significant difference for the likelihood of a given class of SLiMs to be gained via disease-causing variant compared to that of polymorphisms.
Peptide-Protein Interaction Network Analysis 180 peptide-protein interactions that passed the strict LFQ filter and showed significant differential SILAC ratios between wild-type and mutant forms of the peptides were used to compose a peptide-protein interaction network. The network was visualized using Cytoscape 3.5.1 (Shannon et al., 2003) . Sub-graphs of the significant interactions were generated using R package igraph (version 1.0.1) (Csardi and Nepusz, 2006) (using fastgreedy.community function) and visualized using the R packages ggnetwork (Briatte, 2016) and ggplot2 (Wilkinson, 2011) . Enriched GO terms for each sub-graph were calculated using the topGO R package (Alexa and Rahnenfuhrer, 2016) .
QUANTIFICATION AND STATISTICAL ANALYSIS
The type of statistical test (e.g., Mann-Whitney U test or t test) is annotated in the Figure legend and/or in the Methods segment specific to the analysis. In addition, statistical parameters such as the value of n, mean/median, standard error of mean (SEM), standard deviation (SD) and significance level are reported in the figures and/or in the figure legends. When * are used to signify the significance level the key is reported in the respective figure legend. Statistical analyses were generally performed using R as described in METHODS AND DETAILS for each individual analysis, if not stated differently.
Colocalization analysis Imaris v8.4.1 was used for the quantitative colocalization analysis. The original z stack images were adjusted by adding an adequate mask on the respective red channel to subtract background noise (Costes et al., 2004) . The threshold for the mask was uniformly adjusted in each staining experiment. Automatic thresholding was used to define the area where a colocalization would be determined and the statistics was calculated for each colocalization channel (Costes et al., 2004) . For the images whose observed correlation was not statistically significant in comparison to randomized images, the colocalization channel was built without additional thresholding on the masked dataset. The resulting thresholded Pearson's coefficients were exported. The number of images and cells in the analyses is stated in the respective Method sections.
DATA AND SOFTWARE AVAILABILITY
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository. The accession numbers for the peptide-protein interaction screen dataset, the PRM dataset, and the BioID dataset reported in this paper are ProteomeXchange: PXD010027, PXD010005, and PXD010061, respectively. (B) SILAC ratio distributions of detected interactions that can be explained by presence of SLiMs in the peptides and PFAM domains in the interaction partners Peptide-protein interactions detected in the screen were classified as 'gained' or 'lost' according to the following criteria: An interaction is classified as 'gained' if the mutant peptide sequence matches a SLiM pattern that does not match the wild-type peptide sequence and the mutant peptide has an interaction partner that contains a compatible PFAM domain to bind that SLiM instance. On the other hand, an interaction is classified as 'lost' if the wild-type peptide sequence matches a SLiM pattern that is not matched in the mutant peptide sequence and the wild-type peptide has an interaction partner that contains a compatible PFAM domain to bind that SLiM instance. Gained and lost interactions are further sub-classified as 'LFQ positive' and 'LFQ negative' depending on whether the peptide-protein interaction has an LFQ value that passes a looser version of the LFQ cut-off (i.e., p value < 0.05 and log2 fold enrichment > 1). The median SILAC ratio distributions (wild-type versus mutant) of each of these four categories of interactions ('Gained interactions -LFQ negative', 'Gained interactions -LFQ positive', 'Lost interactions -LFQ negative', and 'Lost interactions -LFQ positive') are compared with the median SILAC ratio distributions of all detected interactions from the array using a Wilcoxon-Mann-Whitney test. Compared to the background distribution of median SILAC ratios (in red), the gained interactions that pass the LFQ filter (in green) show a significant negative skew while the lost interactions that pass the LFQ filter (in purple) show a significant positive skew. (C) Impact of specificity cut-off (LFQ) and differential cut-off (SILAC) on peptide candidates After applying the specificity cut-off (derived from control peptide, see STAR Methods) on all interactions, only about half of the 256 (128 variant pairs) peptides showed at least one specific binder according to the LFQ-filter (left pie chart, red). These 120 peptides relate to 76 peptide pairs with specific interactions of wild-type and/or mutant peptide. More than half of all 76 peptide pairs with specific interactors show differential interaction between the variants after applying the SILAC cut-off (see STAR Methods) (right pie chart, red).
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GLUT1_Wt GLUT1_P485L GLUT1_Wt GLUT1_P485L GLUT1_Wt GLUT1_P485L FLAG FLAG FLAG FLAG FLAG Figure S3 . Intracellular Localization of GLUT1_P485L, Related to Figure 4 Quantification of Figure 4B is based on these example images for colocalization study of GLUT1 wild-type and P485L mutant to markers of endocytic compartments. GLUT1 (green), Marker (red), DAPI (blue). CLTC  AP1G1  AP2A1  AP2B1  AP2M1  AP2S1  AP3B1  AP3D1  AP3M1  AP3S1  TUBA1A  CLTC  AP1G1  AP2A1  AP2B1  AP2M1  AP2S1  AP3B1  AP3D1  AP3M1  AP3S1  TUBA1A control peptide (legend continued on next page) (B) Raw elution profiles of transitions from two example peptides from the proteins AP1G1 and AP2A1 for all forward and label swap (reverse) experiments. Ratios were calculated based on extracted intensity informations from the light and heavy channel in each experiment for each transition. Different transitions are displayed with different colors. The spectrum contrast angle (SCA) indicates similarity to the corresponding spectrum in the spectrum library and is displayed for every peak. Figure S5 . iPSCs Show Pluripotency Markers, Related to Figure 6 iPSCs (BIHi037-A) were reprogrammed from a G1DS patient carrying a heterozygous GLUT1 P485L mutation and were stained for known pluripotency markers (see STAR Methods). 
